Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on LinkedIn:
“Interesting publication in Nature Medicine.
Tumor‑informed ctDNA nails MRD detection in CRC, but ALTAIR reminds us detection does not equal intervention.
FTD/TPI didn’t significantly improve DFS and delivered heavy hematologic toxicity. The future is ctDNA‑guided therapy; now we need therapies that can actually move the needle.”
Title: Post-adjuvant chemotherapy in ctDNA-positive patients with resected colorectal cancer: a randomized phase 3 trial
Authors: Hideaki Bando, Jun Watanabe, Yusuke Takahashi, Masahito Kotaka, Nobuhisa Matsuhashi, Eiji Oki, Yoshito Komatsu, Manabu Shiozawa, Keiji Hirata, Yuji Miyamoto, Masanobu Takahashi, Kentaro Yamazaki, Dai Manaka, Akiyoshi Kanazawa, Yi-Hsin Liang, Kun-Huei Yeh, Yuko Watsuji, Yuko Yamamoto, Makoto Fukui, Shruti Sharma, Vasily N. Aushev, Adham Jurdi, Matthew Rabinowitz, Minetta C. Liu, Alexey Aleshin, Ichiro Takemasa, Daisuke Kotani, Akihiro Sato, Toshihiro Misumi, Yoshiaki Nakamura, Qian Shi, Hiroya Taniguchi, Takayuki Yoshino and Takeshi Kato
Other articles about Vivek Subbiah on OncoDaily.